Editorial Comment from Dr Matsuo et al. to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial

Affiliations

Editorial

Tomohiro Matsuo et al. Int J Urol. 2022 May.

. 2022 May;29(5):397.

doi: 10.1111/iju.14820. Epub 2022 Feb 10.

¹ Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

No abstract available

Comment on

Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Elbaz R, El-Assmy A, Zahran MH, Hashem A, Shokeir AA. Elbaz R, et al. Int J Urol. 2022 May;29(5):390-396. doi: 10.1111/iju.14792. Epub 2022 Jan 18. Int J Urol. 2022. PMID: 35043484 Clinical Trial.

1. Roehrborn CG, Manyak MJ, Palacios-Moreno JM et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018; 121: 647-58.
1. Elbaz R, El-Assmy A, Zahran MH, Hashem A, Shokeir AA. Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. Int. J. Urol. 2022; 29: 390-6.
1. de Oliveira MG, Rojas-Moscoso JA, Bertollotto GM et al. Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response. Eur. J. Pharmacol. 2019; 858: 172447.
1. Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Salvatore S, Serati M. Mirabegron in female patients with overactive bladder syndrome: what’s new? A systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 251: 73-82.